New Ebola vaccine may have 100% efficacy
Source: National Institute of Allergy and Infectious Diseases (NIAID)
Developing a vaccine against Ebola has been a priority since the largest recorded epidemic of the disease in West Africa began in summer 2014. With funding primarily from the World Health Organization, a new vaccine against the Zaire Ebola strain was tested in a phase III trial involving 7,651 people in Guinea.
In a process called ‘ring vaccination’, new cases of Ebola were laboratory-confirmed and all of the individual’s contacts, as well as contacts of contacts, identified. When contacts were vaccinated immediately, there were no new cases of Ebola. However, in the control group, vaccination was delayed by 21 days and there were 16 cases. This suggests a vaccine efficacy of 100% (95% confidence interval 74·7–100·0; P=0·0036).
The vaccine seems to be highly efficacious and safe, conclude the authors of the study in The Lancet (online, 31 July 2015).
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069162
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now